Skip Main Navigation | Skip to Content

Heidi McNaney-Flint

Heidi McNaney-Flint

Clerkship Director

heidi.mcnaney-flint@med.fsu.edu
(772) 464-0034
Ft. Pierce Regional Campus

Job Description

Dr. McNaney-Flint coordinates the OB-GYN curriculum and training of third- and fourth-year medical students at the Ft. Pierce Regional Campus.

Biosketch

Dr. McNaney-Flint has been in practice on the Treasure Coast for 31 years. She began in Vero Beach in 1984 as a staff OB-GYN at a multispecialty clinic. She relocated to Stuart in 1986 to start her own practice. She was the medical director of The Women’s Center of Martin County (Birthing Center) from 1986 to 2002. In 1988 she brought in an associate and the practice was known as Physicians to Women. After the addition of multiple physicians and nurse practitioners, she left PTW in 2000 to return to solo practice in gynecology and gynecologic surgery. She served as FSU clerkship faculty from 2007 to 2014. In 2015 she transitioned her practice to ambulatory gynecology and became the FSU Fort Pierce campus OB-GYN Clerkship Director.

Education

Rollins College, B.A. 1977

University of South Florida College of Medicine, M.D. 1980

University of Virginia School of Medicine Obstetrics and Gynecology Residency 1984

Board Certified 1986, 2005, 2014, and now annually through MOC
Fellow, ACOG

Memberships

Board Certified 1986, 2005, 2014, and now annually through MOC
Fellow, ACOG

Research Focus

Principal Investigator
FDA 511-07
A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Finbancerin 25mg BID and 50mg QD in premenopausal women with hypo-active sexual disorder in North America. Boehringer Ingelheim Pharmaceuticals. 2006-2008

FDA DR-CEN 302
A randomized, multi-center, double-blind, placebo-controlled trial to compare the effects of twelve weeks of treatment with DR-2041 vagina cream vs placebo vaginal cream on vulvo-vaginal atrophy in healthy postmenopausal woman. Barr pharmaceuticals 2006-2007.

FDA HMR4003B/4033
An eighteen-month, multi-center, parallel-group study to determine the relative efficacy of Risedronate vs Raloxifene in subjects who have discontinued hormone replacement therapy, for early intervention in osteoporosis. Avenues Pharma. 2004-2005

FDA 102.31.02
Double-blind investigation of efficacy and safety of continuous or sequential dihydroprogesterone in combination with 1mg continuous 17-beta estradiol compared to 1mg continuous 17-beta estradiol alone for the prevention of estrogen-induced endometrial hyperplasia in postmenopausal women. Solvay Pharmaceuticals. 1992-1996

FDA 102.02.03
Pilot study of the cellular and histologic endometrial effects of continuous esterified estrogen in combination with different doses of continuous or cyclic dihydroprogesterone in postmenopausal women. Solvay Pharmaceuticals. 1992-1996.

Publications

Knuppel, RA and McNaney, HM.”Idiopathic Thrombocytopenic Purpura in Pregnancy.” in Reid’s Controversy in Obstetrics and Gynecology III, Zuspan and Christion Eds, Sanders 1983.

Genant, HK, Lucas J, McNaney-Flint, H et al. Low Dose Esterified Estrogen Therapy. Annals of Internal Medicine 1997; 157: 2609-2616.